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FGF21 Mediates the Thermogenic and
Insulin-Sensitizing Effects of Dietary
Methionine Restriction but Not Its
Effects on Hepatic Lipid Metabolism
Diabetes 2017;66:858–867 | DOI: 10.2337/db16-1212
Dietary methionine restriction (MR) produces a rapid and
persistent remodeling of white adipose tissue (WAT), an
increase in energy expenditure (EE), and enhancement of
insulin sensitivity. Recent work established that hepatic
expression of FGF21 is robustly increased byMR. Fgf212/2
mice were used to test whether FGF21 is an essential
mediator of the physiological effects of dietary MR. The
MR-induced increase in energy intake and EE and activa-
tion of thermogenesis in WAT and brown adipose tissue
were lost in Fgf212/2 mice. However, dietary MR produced
a comparable reduction in body weight and adiposity in
both genotypes because of a negative effect of MR on
energy intake in Fgf212/2 mice. Despite the similar loss in
weight, dietary MR produced a more significant increase
in in vivo insulin sensitivity in wild-type than in Fgf212/2
mice, particularly in heart and inguinal WAT. In contrast,
the ability of MR to regulate lipogenic and integrated stress
response genes in liver was not compromised in Fgf212/2
mice. Collectively, these findings illustrate that FGF21 is a
critical mediator of the effects of dietary MR on EE, remod-
eling of WAT, and increased insulin sensitivity but not of its
effects on hepatic gene expression.
Dietary methionine restriction (MR) produces an integrated
series of metabolic and physiological responses that persis-
tently improve biomarkers of metabolic health (1–3). The
most prominent physiological responses are coordinated in-
creases in energy intake and expenditure (2), with the larger
effect on energy expenditure (EE) limiting net increases in
fat deposition and accumulation of body weight (BW) (4).
The MR diet also increases in vivo insulin sensitivity
through a combination of direct and indirect effects on
the liver, adipose tissue, and muscle (5). Although prog-
ress has been made in identifying the molecular sensors
that detect MR (6–13), a full accounting of the specific
mechanisms linking reduced methionine to its metabolic
phenotype remains incomplete. The MR-induced improve-
ment in insulin sensitivity is partly due to reductions in
adiposity, but the MR diet also increases tissue-specific in-
sulin sensitivity through mechanisms that are independent
of differences in adiposity (4). For example, MR-dependent
reductions in hepatic glutathione significantly enhance
insulin signaling by slowing glutathione-dependent degrada-
tion of PIP3 (5). Dietary MR also increases secretion of the
insulin sensitizer, adiponectin, from adipose tissue (2,3,14),
but the ability of MR to enhance insulin sensitivity appears
uncompromised in adiponectin-null mice (15).
Another promising mediator of the physiological
effects of dietary MR is FGF21. Within hours of initiating
dietary MR, hepatic transcription and release of FGF21
into the serum is increased by four- to fivefold (5,13). The
evidence is compelling that FGF21 is a powerful metabolic
regulator in the context of glucose homeostasis, lipid me-
tabolism, and energy balance (16–22), but controversy
remains about how FGF21 signaling is anatomically orga-
nized to produce its multiple physiological effects. To
date, the biological responses to FGF21 have been cata-
loged in studies where FGF21 was infused at high doses or
increased via transgenic overexpression, so whether the
physiological increases produced by MR are sufficient to
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elicit all of the responses produced by pharmacological
modulation of FGF21 is unclear (23). However, many if
not most of the metabolic, transcriptional, and signaling
effects attributed to FGF21 are fully reproduced by dietary
MR (1,2,4,5,24). Using Fgf212/2 mice and dietary MR in
both low-fat and high-fat (HF) contexts, we report here
that FGF21 is an essential mediator of the effects of MR
on EE and energy intake but not overall energy balance due
to a paradoxical decrease in intake of the MR diet in
Fgf212/2 mice. The greater enhancement of insulin sensi-
tivity by MR in wild-type (WT) versus Fgf212/2 mice, de-
spite a comparable loss of BW, suggests a partial but
significant FGF21-dependent role in the mechanism. In
contrast, the expected transcriptional responses to MR in
the liver are fully intact in Fgf212/2 mice, supporting a
FGF21-independent mechanism of action.
RESEARCH DESIGN AND METHODS
The vertebrate animal experiments in this study were
reviewed and approved by the Pennington Institutional
Animal Care and Use Committee using guidelines estab-
lished by the National Research Council, the Animal Welfare
Act, and the Public Health Service Policy on humane care
and use of animals.
Animals and Diets
Fgf212/2 mice on the C57BL/6J genetic background were
provided by Dr. Steven Kliewer (UT Southwestern). Two
different dietary formulations of the control (CON) and
MR diets, differing in energy density, were manufactured
by Dyets Inc. (Bethlehem, PA). The energy content of the
CON (Dyets #510072) and MR diets (Dyets #510071)
used in experiments 1–3 was 15.96 kJ/g, with 18.9% of
energy from fat (corn oil), 64.9% from carbohydrate, and
14.8% from a custom mixture of L-amino acids. The
amino acid content of the diets on a weight basis was
14.1%. The CON diet contained 0.86% methionine, and
the MR diet contained 0.17% methionine. For experiment
4, the energy density of the CON and MR diets was
increased to 22.8 kJ/g, with 59.6% of energy from fat
(lard and soybean oil), 25.7% from carbohydrate, and
14.7% from L-amino acids. The HF CON diet contained
0.86% methionine, and the HF MR diet contained
0.17% methionine. Food and water were provided ad
libitum, and lights were on 12 h/day from 7 A.M. to 7 P.M.
Mice were euthanized by CO2 narcosis, followed by
decapitation.
Experiment 1
Five-week-old male WT (n = 16) and Fgf212/2 (n = 16)
C57BL/6J mice were acclimated to the CON diet for
1 week before the mice were adapted to the TSE Indirect
Calorimetry system. All mice received the CON diet during
the adaptation period. Thereafter, eight mice of each geno-
type were switched to the MR diet and eight mice of each
genotype continued on the CON diet. VO2 and VCO2
were measured at 40-min intervals for an additional
11–12 days. The respiratory quotient (RQ) was calculated
as the ratio of VCO2 produced to VO2 consumed. EE was
calculated as (VO2*[3.815 + {1.232*RQ}]*4.1868).
Experiment 2
Five-week old male WT (n = 20) and Fgf212/2 (n = 20)
C57BL/6J mice were acclimated to the CON diet for
1 week, and then half the mice of each genotype were
switched to the MR diet while the other half continued
on the CON diet. Food intake, BW, and composition were
measured weekly for 9 weeks before all mice were adapted
to the TSE system for 2 days, followed by measurement of
VO2, VCO2, activity, and food intake at 40-min intervals
for 3 days. Mice were euthanized 1 week later, and tissues
were harvested after a 4-h fast. Group differences in EE
(kJ/mouse/h) were compared using ANCOVA (JMP Sta-
tistical Software, version 11; SAS Institute Inc., Cary, NC),
calculating least squares means that accounted for varia-
tion in EE attributable to differences in lean mass, fat
mass, activity, energy intake, genotype, diet, and geno-
type 3 diet interaction (4). The least squares means 6
SEM for the genotype 3 diet combinations were com-
pared using a two-way ANOVA, and the significance of
the model effects and interaction were tested using resi-
dual variance calculated by ANCOVA.
Experiment 3
A third cohort of WT (n = 20) and Fgf212/2 (n = 20) mice
was shipped to the Vanderbilt Phenotyping Center at 5 weeks
of age to undergo hyperinsulinemic-euglycemic clamps as
previously described (5,25). Mice of each genotype were
fed the CON diet for 3 weeks before being randomized to
the CON or MR diet for the following 13 weeks before
surgery for catheter placement. After a 5-day recovery,
clamps were performed in conscious mice after a 5-h fast.
Insulin (2.5 mU/kg/min) was infused with a 50% dextrose
solution at a variable rate to maintain euglycemia. Whole-
body glucose turnover was assessed with a 5 mCi bolus of
[3-3H]glucose tracer 1.5 h before insulin treatment, followed
by a 0.05 mCi/min infusion during the clamp. Insulin-
stimulated glucose uptake in individual organs was
determined using 2-[14C]deoxyglucose ([14C]2-DG) admin-
istered as a single bolus (13 mCi) 120 min after the start of
clamp procedure. At t = 145 min, epididymal WAT, inguinal
WAT (IWAT), brown adipose tissue (BAT), gastrocnemius
muscle, vastus lateralis muscle, soleus muscle, brain, and
heart were harvested for analysis. Steady-state glucose in-
fusion rates (GIRs), glucose levels, plasma insulin, BWs,
and Rg in each tissue were compared by two-way ANOVA.
Experiment 4
Male WT (n = 24) and Fgf212/2 (n = 24) C57BL/6J mice
(12 weeks old) were acclimated to the HF CON diet for
4 weeks before half of the mice of each genotype were
switched to the HF MR diet. Food intake, BW, and compo-
sition were measured weekly for 8 weeks. After a 2-week
recovery, mice were adapted to TSE system for 2 days, fol-
lowed by measurement of VO2, VCO2, activity, and food
intake at 40-min intervals for 3 days. Data were analyzed
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as described for experiment 2. Tissues and serum were
harvested 1 week after indirect calorimetry after a 4-h fast.
Western Blotting
Expression of fatty acid synthase (FASN), and stearyl-CoA
desaturase (SCD-1) were measured by Western blotting as
previously described (1). The FASN antibody was from
Santa Cruz (Dallas, TX), the b-actin antibody was from
Sigma-Aldrich (St. Louis, MO), and the affinity-purified
SCD-1 antibody was described previously (1). Detected
proteins were quantitated using ImageJ software, and the
relative expression of the target protein versus b-actin was
calculated to test for genotype and diet effects.
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated using an RNeasy Mini Kit (QIAGEN
Inc., Valencia, CA). One microgram of total RNA was reverse
transcribed to produce cDNA. Gene expression was mea-
sured by real-time PCR (Applied Biosystems, Foster City,
CA) by measurement of SYBR Green. mRNA concentrations
were normalized to cyclophilin expression.
Histology
Paraffin-embedded IWAT tissues from experiment 1 were
sectioned at 5 mm and stained for hematoxylin and eosin
as previously described (26).
Liver and Serum Triglyceride
Serum and lipid triglyceride levels were measured as pre-
viously described (2).
RESULTS
Role of FGF21 in MR-Induced Effects on EE
and Energy Balance
Comparison of the acute effects of dietary MR on EE in
WT and Fgf212/2 mice showed that the diet significantly
increased EE at day 6 in WT mice and expanded the mag-
nitude of the effect over the subsequent 6 days (Fig. 1A). In
Figure 1—Assessment of acute and chronic effects of dietary MR on EE and energy balance in WT and Fgf212/2 mice. EE was measured by
indirect calorimetry in WT (A) and Fgf212/2 mice (B). Mice fed the CON diet were placed in the TSE calorimeters and were randomized to
remain on CON or switched to MR while in the TSE. The effect of diet on 24-h EE was compared for each day within genotype during the
following 11 days. Days annotated with an * differ from mice fed the CON diet at P < 0.05. Change in BW (C), fat mass (D), energy intake per
mouse (E), and energy intake per unit BW (F) for 9 weeks in WT and Fgf212/2 mice after initiation of dietary MR. Means6 SEM are presented
for weekly measurements in 8 mice per diet per genotype, and means annotated with * and # differ from mice of the same genotype fed the
CON diet at P < 0.05. Least squares means 6 SEM of EE (G) and RQ (H) determined after 9 weeks on respective diets and measured over
3 days in eight mice per diet per genotype. Least squares means of EE were calculated by ANCOVA as described in RESEARCH DESIGN AND
METHODS. EE and RQ were compared by a two-way ANOVA. Means annotated with a different letter (a, b, c) differ at P < 0.05. I: Hematoxylin
and eosin stains of representative sections of IWAT from WT and Fgf212/2 mice fed the CON or MR diet for 9 weeks.
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contrast, dietary MR had no effect on EE in Fgf212/2 mice
in the first 11 days the diet was provided (Fig. 1B), sup-
porting the view that FGF21 is required for the acute in-
crease in EE produced by MR.
BW of WT and Fgf212/2 mice fed the CON diet did not
differ at the beginning of experiment 2, but BW diverged
slightly over the final 5 weeks, with WT mice ending the
study slightly but not significantly heavier than Fgf212/2
mice (Fig. 1C). In WT and Fgf212/2 mice fed the CON diet,
the change in fat mass over time paralleled the change in
BW (Fig. 1D). This difference in BW in mice fed the CON
diet is reflected in the slightly but not significantly higher
energy intake in WT mice compared with Fgf212/2 mice
(Fig. 1E). Dietary MR produced a significant increase in
energy intake in WT mice during the entire study (Fig.
1E), but their accumulation of BW and fat mass was sig-
nificantly lower than WT mice fed the CON diet (Fig.
1C and D). In contrast, MR decreased energy intake
in Fgf212/2 mice after 4 weeks, and the decrease trans-
lated into reduced accumulation of BW and fat mass in
Fgf212/2 mice fed the MR diet (Fig. 1C and D). However,
the identical energy intake per unit BW of Fgf212/2 mice
fed the respective diets indicates that the loss in BW and fat
mass of Fgf212/2 mice fed the MR diet is accounted for by
their reduction in intake per mouse (Fig. 1E and F). The
primary effect of MR on body composition in both geno-
types was to reduce fat deposition (Fig. 1D), but the mech-
anism in WT mice was an increase in EE (Fig. 1A and G),
whereas the mechanism in Fgf212/2 mice was reduced en-
ergy intake (Fig. 1E). The indirect calorimetry conducted at
the end of the study showed that MR significantly increased
EE in WT mice but was without effect in Fgf212/2 mice (Fig.
1G). Dietary MR failed to reduce RQ in either genotype, and
the RQs were similar across genotypes within the diet (Fig.
1H). The appearance of WAT was also differentially affected
by MR between the genotypes, with MR producing the pre-
viously shown remodeling of cell and fat droplet morphology
in the inguinal depot (4,27) of WT mice and only a modest
reduction in adipocyte size in Fgf212/2 mice (Fig. 1I). To-
gether, these findings illustrate that FGF21 is an essential
mediator of the effects of dietary MR on energy intake, EE,
and remodeling of WAT.
Role of FGF21 in MR-Induced Effects on Insulin
Sensitivity
We previously showed that dietary MR for 8–10 weeks
produces a two- to threefold increase in overall insulin
sensitivity (5,13). To test whether FGF21 was an essential
mediator of this effect, hyperinsulinemic-euglycemic
clamps were used to assess insulin sensitivity in WT
and Fgf212/2 mice. The GIRs needed to establish eugly-
cemia after the insulin infusion was initiated were com-
parable between WT and Fgf212/2 mice fed the CON diet,
and MR produced a significant increase in steady-state
GIR between 80 to 120 min in both genotypes (Fig. 2A).
The steady-state levels of blood glucose during the clamp
were comparable among the groups (Fig. 2B), as were
plasma insulin levels before and during the clamp (Fig.
2C). The MR-dependent increase in GIR in WT mice was
nearly threefold, whereas the increase in Fgf212/2 mice
was approximately twofold (Fig. 2A). MR produced a com-
parable reduction in BW in this study (Fig. 2D) and a
slightly greater reduction in fat mass in experiment
2 (Fig. 1D). Thus, the slightly greater improvement in over-
all insulin sensitivity produced by MR in WT compared
with Fgf212/2 mice suggests a body size– or composition-
independent component of the improvement in insulin
sensitivity that is FGF21 dependent (Fig. 2A). The Rg pro-
vides a measure of insulin-dependent plus -independent
glucose uptake and showed that MR enhanced [14C]2-DG
uptake by two- to threefold in gastrocnemius muscle,
vastus lateralis muscle, soleus muscle, and heart in WT
mice (Fig. 2E and F). In contrast, the MR-dependent in-
crease in skeletal muscle Rg in Fgf21
2/2 mice was interme-
diate in that it did not differ from Fgf212/2 mice fed the
CON diet or WT mice fed the MR diet (Fig. 2E). In the
heart, MR had no detectable effect on Rg in Fgf21
2/2 mice
(Fig. 2F). MR did increase Rg by fourfold in IWAT of
Fgf212/2 mice, whereas the increase in WT mice was nine-
fold, indicating a more significant effect of MR when
FGF21 was present (Fig. 2G). Together, these data provide
compelling evidence that FGF21 is an essential mediator of
the insulin-sensitizing effects of MR, working through both
weight-dependent and -independent mechanisms.
Role of FGF21 in Reversal of Diet-Induced Obesity
by Dietary MR
After WT and Fgf212/2 mice were adapted to the HF
CON diet for 4 weeks, initiation of the HF MR diet pro-
duced an immediate and comparable reversal of BW (Fig.
3A) and fat accumulation (Fig. 3B) in both genotypes.
During this first 4-week period, BW and fat mass de-
creased in parallel in each genotype and remained essen-
tially constant during the last 4 weeks of the study (Fig.
3A and B). By comparison, the BW and fat mass of WT
and Fgf212/2 mice fed the HF CON diet steadily in-
creased during the 8-week study (Fig. 3A and B). The
40% reduction in BW of WT mice fed the HF MR diet
versus the HF CON diet occurred despite a 30% higher
rate of energy intake in WT mice fed the HF MR diet
compared with the HF CON diet (Fig. 3C). Even after
energy intake was adjusted to the difference in BW, WT
mice fed the HF MR diet were still consuming signifi-
cantly more than WT mice fed the HF CON diet (Fig.
3D), indicative of a higher rate of EE. In contrast, the
rapid and significant loss of BW in Fgf212/2 mice fed
the HF MR diet is entirely attributable to a reduction in
energy intake that becomes evident after 2 weeks and
persists for 4 of the 8 weeks of the study (Fig. 3C). Mea-
surements of EE after 9 weeks on the respective diets
support this conclusion and show that MR produced a
significant increase in EE in WT but not Fgf212/2 mice
(Fig. 3E). The HF configurations of the CON and MR diets
reduced RQs to ;0.8 in all groups, and no genotype, diet,
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or genotype3 diet interactions were detected (Fig. 3F). Thus,
in both low-fat and HF contexts, FGF21 appears to be an
essential mediator of MR’s effect on energy intake and EE.
Role of FGF21 as a Mediator of Transcriptional
Effects of Dietary MR in the Liver
To examine the role of FGF21 as a mediator of the trans-
criptional effects of MR in the liver, previously identified
targets of MR were measured in mice from experiment 4.
For example, previous studies identified lipogenic genes as
targets and showed that MR produced a coordinated
downregulation of these genes (1). Examination of the
key genes involved in hepatic de novo lipogenesis (e.g.,
Scd1, Fasn, Acc1) in WT and Fgf212/2 mice showed that
the HF MR diet reduced Scd1 mRNA expression by ;10-
fold and Fasn mRNA by ;2-fold in WT and Fgf212/2
mice (Fig. 4A). The reduction in hepatic Acc1 mRNA by
MR was not significant in either genotype. Dietary MR
also produced comparable reductions in SCD-1 (Fig. 4B)
and FASN (Fig. 4C) protein expression in both genotypes.
Hepatic triglyceride levels were reduced by twofold by MR
in WT mice and were accompanied by a significant decrease
in serum triglycerides (Fig. 4D). MR produced a larger
threefold reduction in hepatic triglycerides in Fgf212/2
mice but had no effect on serum triglycerides. We recently
showed that MR regulated the integrated stress response in
liver by activation of NRF2 and ATF4 (13). Figure 4E shows
that the transcriptional activation of genes from these path-
ways was comparable between WT and Fgf212/2 mice. To-
gether, these findings support the view that FGF21 is not
required for MR-dependent regulation of lipogenic, NRF2-
dependent, or ATF4-dependent genes in the liver.
Role of FGF21 as a Mediator of Transcriptional
Effects of Dietary MR in Adipose Tissue
Consumption of a MR diet induces significant browning
of WAT and activation of thermogenesis in BAT (2,4,14,27).
The MR diet also remodels WAT lipid metabolism by upre-
gulating lipogenic gene expression (1). To explore the role of
FGF21 in MR-dependent transcriptional responses in BAT
Figure 2—Hyperinsulinemic-euglycemic clamps in WT and Fgf212/2 mice after 13 weeks of dietary MR to test for effects on overall insulin
sensitivity and insulin-dependent 2-DG uptake among tissues. The clamp procedures were conducted as described in RESEARCH DESIGN ANDMETHODS.
A: The GIR required to maintain euglycemia during the insulin clamps is shown. Blood glucose concentration (B) and plasma insulin concentration (C)
are shown before and during the insulin clamps. D: The effect of the CON and MR diets on the respective BWs of WT and Fgf212/2 mice is shown.
Rg is shown for skeletal muscle (E); BAT, heart, and brain (F); and epididymal WAT (EWAT) and IWAT (G).Rg provides ameasure of insulin-dependent
plus insulin-independent glucose uptake in each tissue. TheRg for each tissue were compared by two-way ANOVA andmeans6 SEM are based on
n = 7–9 mice per genotype and diet. Means annotated with different letters (a, b, c) within each tissue differ at P < 0.05.
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and WAT, we measured transcriptional markers of thermo-
genesis in BAT and lipogenesis and browning in IWAT from
each genotype of experiment 4. In WT mice, the HF MR diet
produced significant increases in markers of thermogenesis
(Ucp1, Bmp8b, Cidea, Elov3) in BAT (Fig. 5A), lipogenesis
(Scd1, Fasn, Acc1, Elovl6) in IWAT (Fig. 5B), and thermogenic
remodeling (Ucp1, Cox7a1, Cox8b, Cidea) in IWAT (Fig. 5C). In
contrast, with the exception of a positive effect on Acc1 in
IWAT, the MR diet was ineffective in inducing the thermo-
genic or lipogenic programs in BAT and WAT of Fgf212/2
mice (Fig. 5A–C). Together these findings illustrate that
FGF21 is an essential mediator of the transcriptional pro-
grams induced by dietary MR in BAT and WAT.
DISCUSSION
Dietary MR produces a coordinated series of biochemi-
cal and physiological responses that develop soon after
initiation of MR and persist for as long as the diet is
consumed (3,14,28–31). The biological significance of
these effects in aggregate is substantial, resulting in ani-
mals that are leaner, more insulin sensitive, and live
longer (1,2,24,32,33). The most significant unanswered
questions pertain to how the reduction in dietary methi-
onine is sensed and how these sensing mechanisms are
coupled to tissue-specific responses that produce the
resulting metabolic phenotype. Previous studies establish
that dietary MR produces a rapid, robust, and persistent
increase in hepatic transcription and release of FGF21
(4,5,15,34). The evidence is also compelling that FGF21
is a powerful metabolic regulator in the context of glu-
cose homeostasis, lipid metabolism, and energy balance
(16–22), but controversy remains about how FGF21 signal-
ing is anatomically organized to produce its multiple phys-
iological effects. The biological responses to FGF21 have
been documented in studies where FGF21 was infused at
high doses or increased via transgenic overexpression, so it
Figure 3—Assessment of chronic effects of HF CON and HF dietary MR on energy balance and EE in WT and Fgf212/2 mice. WT and
Fgf212/2 mice (12 weeks old) were fed the HF CON diet for 4 weeks before half of the mice of each genotype were randomized to remain
on the HF CON diet and the remaining half of mice were switched to the HF MR diet. Change in BW (A), fat mass (B), energy intake per
mouse (C), and energy intake per unit BW (D) for 8 weeks in WT and Fgf212/2 mice after initiation of dietary MR. Means 6 SEM are
presented for weekly measurements in 10 mice per diet per genotype. Means annotated with symbols (*, #) differ from mice of the same
genotype fed the CON diet at P< 0.05. Least squares means6 SEM of EE (E) and RQ (F) determined after 8 weeks on respective diets and
measured over 3 days in eight mice per diet per genotype (E). Means annotated with a different letter (a, b, and c) differ at P < 0.05.
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is unclear whether the physiological increases produced by
MR (e.g., 1 ng/mL to 8 ng/mL [13]) are sufficient to elicit
all of the responses produced by pharmacological modu-
lation of FGF21 (23). Many of the metabolic, transcrip-
tional, and signaling effects attributed to FGF21 are fully
reproduced by dietary MR (1,2,4,5,24). For example,
FGF21 directly affects adiponectin secretion from adipo-
cytes (35), increases lipogenic gene expression in WAT
(16), promotes browning of WAT (36), and increases ther-
mogenic gene expression in BAT and WAT (36). Dietary
MR produces significant browning of WAT (1,2,27), and
given the increased glucose uptake and utilization associ-
ated with browning (37), the suggestion that MR is func-
tioning through this mechanism to increase insulin
sensitivity in WAT is attractive. However, recent reports
argue that the glycemic improvements produced by
FGF21 are independent of browning in WAT (38, 39)
and are dependent on direct effects of FGF21 in adipose
tissue (5,18,40,41). This view is also supported by studies
showing that pegylated FGF21, which is too large to pen-
etrate the central nervous system (CNS), is fully effective
in normalizing glucose utilization in insulin-resistant states
(42). However, from the findings presented here, it seems
clear that MR-dependent increases in FGF21 affect tissue-
specific and overall insulin sensitivity through a combina-
tion of mechanisms involving both decreased adiposity and
direct effects of FGF21 in specific tissues.
Our previous work focused on liver and adipose tissue
not only as primary transcriptional targets of dietary MR
(1,24) but also as key sites for the insulin-sensitizing
effects of the diet (5,13). The current study provides in-
triguing new observations supporting the view that 1) the
heart is an important target for the enhancement of in-
sulin-dependent glucose uptake by dietary MR and that 2)
FGF21 is required for the MR-dependent enhancement of
cardiac glucose uptake (Fig. 2F). Given the contribution of
the heart to whole-body glucose disposal in the mouse, it
seems likely that the MR-dependent increase in FGF21
plays a key role in enhancing overall insulin-dependent
glucose utilization through its effects on cardiac glucose
uptake. Pharmacological administration of FGF21 was also
shown to increase glucose uptake in the heart (22), but the
present observations are the first to our knowledge of
physiologically relevant alterations of FGF21 enhancing
insulin-dependent glucose uptake in the heart. Mice lacking
the intestinal and renal neutral amino acid transporter
(e.g., Slc6a19) that transports dietary methionine into
the enterocyte have impaired absorption of dietary
Figure 4—Effects of HF CON and HF dietary MR on hepatic gene expression and on liver and serum triglycerides in WT and Fgf212/2 mice.
WT and Fgf212/2 mice (12 weeks old) were fed the HF CON diet for 4 weeks before half the mice of each genotype were randomized to
remain on the HF CON diet and the remaining half of mice were switched to the HF MR diet for 8 weeks. Effects of MR on hepatic lipogenic
gene expression (A and B) or NRF2-sensitive and ATF4-sensitive gene expression (E) were expressed as fold change in the MR group/CON
group within genotype for each gene (A and E). The respective mRNAs were measured by real-time PCR. Expression of SCD-1 (B) and
FASN (C) was determined in representative liver microsomes for SCD-1 and cytosol for FASN in mice from each genotype and diet.
Expression of SCD-1 and FASN were expressed relative to b-actin. D: Serum and liver triglycerides were measured as described in
RESEARCHDESIGN ANDMETHODS. Means in panel D that are annotated with different letters (a, b, c) within tissue differ at P < 0.05 (n = 10/group).
Fold-changes in expression for each gene in panels A and E are representative of 10 mice per diet per genotype. Means annotated with
an * differ from the CON diet within genotype at P < 0.05.
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methionine and increased methionine excretion (43). Inter-
estingly, Slc6a192/2 mice have elevated circulating FGF21
concentrations and enhanced glucose uptake, especially in
the heart (44). In contrast, liver-specific deletion of FGF21
does not seem to affect glucose uptake by the heart (45).
Considered together, the present findings make a compelling
case that the heart is an important metabolic target of
dietary MR by virtue of MR’s enhancement of hepatic
transcription and release of FGF21. In addition to direct
effects in peripheral tissues, FGF21 also acts centrally.
Although all of the CNS sites where FGF21 is acting re-
main ill defined, FGF21 affects EE through an increase
in sympathetic nervous system outflow to adipose tissue
(21,35,46,47). Dietary MR increases core temperature, EE,
and thermogenic function in BAT and WAT through in-
creases in sympathetic nervous system stimulation of
adipose tissue (2,14). Our present findings make a com-
pelling case that the MR-dependent increase in hepatic
FGF21 is the key event linking MR to its metabolic
effects on EE through remodeling of adipose tissue
and enhanced thermogenic capacity. Sorting out the rela-
tive contributions of peripheral versus central FGF21 signal-
ing during MR will require careful phenotyping of loss of
MR-dependent effects after selective deletion of FGF21
signaling in the respective sites.
Comparisons of energy balance of WT and Fgf212/2
mice fed CON diets are also important in interpreting the
present findings. In mice fed the low-fat CON diet, BWs of
Fgf212/2 mice trended lower by the end of the study, and
this was likely the product of slightly lower energy intakes
and EE in Fgf212/2 compared with WT mice (Fig. 1C, E,
and G). This finding differs slightly from our earlier finding
of similar EE in WT and Fgf212/2 mice (13) but agrees with
previous reports of lower EE in Fgf212/2 compared with
WT mice (48, 49). In contrast, BWs were lower in Fgf212/2
than WT mice after 12 weeks on the HF CON diet (Fig. 3A),
and this occurred despite similar intake of the HF CON diet
during the study (Fig. 3C). Interestingly, EE in Fgf212/2
mice fed the HF CON diet was 6.4% higher than WT mice
(Fig. 3E), suggesting that the higher EE at equivalent energy
intake may have translated into reductions of BWs in
Fgf212/2 mice. Previous reports have detected no differ-
ences in BWs between WT and Fgf212/2 mice fed HF diets
(50,51), although the mice in those studies were somewhat
older than the mice used in this study.
The most surprising finding from the present work is
that Fgf212/2 mice fed the MR diet lost as much BW and
adiposity as WT mice. However, careful examination of the
data (Figs. 1 and 3) illustrates that MR affected weight and
adiposity in WT and Fgf212/2 mice through completely
different mechanisms. For example, despite increasing en-
ergy intake and EE in WT mice, the MR diet limited adipose
tissue accretion because of its proportionately larger effect
on EE. In contrast, the MR diet had no effect on EE in
Fgf212/2 mice and actually reduced their energy intake to
levels below that of Fgf212/2 mice fed the CON diet (Figs.
1E and 3C). This translated into comparable negative energy
balances between WT and Fgf212/2 mice fed the MR diet.
A further illustration that the weight loss of Fgf212/2 mice
fed the MR diet is exactly proportional to their decrease in
intake is obtained by expressing energy intake per unit BW.
Figures 1E and 3D show that the decreased weight gain in
Fgf212/2 mice fed the MR diet, relative to Fgf212/2 mice
fed the CON diet, is exactly proportional to their decrease in
intake. This interpretation assumes that MR is not altering
EE in Fgf212/2 mice fed the MR diet, which was confirmed
by independent measurements of EE in these mice.
The mechanism underlying the negative effect of MR
on energy intake in Fgf212/2 mice is unknown. Low-protein
(LP) diets recapitulate the effects of MR on hepatic release
Figure 5—Effects of HF CON and HF dietary MR on gene expression
in BAT andWAT fromWT and Fgf212/2 mice. WT and Fgf212/2 mice
(12 weeks old) were fed the HF CON diet for 4 weeks before half of
the mice of each genotype were randomized to remain on the HF
CON diet and the remaining half of mice were switched to the HF MR
diet for 8 weeks. Effects of MR on thermogenic gene expression in
BAT (A), lipogenic gene expression in IWAT (B), and browning genes
in IWAT (C) were expressed as fold change in the MR group/CON
group within genotype for mRNA levels for each gene and tissue. The
respective mRNAs were measured by real-time PCR, and the means
are representative of 10 mice per diet per genotype. Means anno-
tated with an * differ from the CON diet within genotype at P < 0.05.
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of FGF21, increased energy intake, and increased EE in WT
mice, but recent work showed that the LP diet did not pro-
duce hypophagia in Fgf212/2 mice (52). Because of this
neutral effect on food intake, Fgf212/2 mice fed the LP
diet grew at the same rate as WT mice fed the CON diet
(52). A negative effect of MR on energy intake was also
observed in Ucp12/2 mice, where the MR diet also failed
to increase EE (4). Thus, a common feature of MR’s inability
to increase EE in Fgf212/2 and Ucp12/2 mice was the neg-
ative effect of the MR diet on energy intake. One interpre-
tation of these data is that the MR-dependent increase in
energy intake is dependent on a coordinated MR-dependent
increase in EE. Arguing against such a mechanism are the
effects of dietary leucine deprivation, which results in food
aversion despite a significant increase in EE (53–55). Per-
haps the absence of FGF21 heightens the central perception
of reduced methionine such that it is interpreted as methi-
onine deprivation with respect to energy intake. Cell type–
specific deletion of FGF21 signaling in CNS sites involved in
essential amino acid sensing would be one approach to test
this possibility.
The previously reported activation of NRF2-sensitive and
ATF4-sensitive genes by MR and the downregulation of
hepatic lipogenic genes and tissue triglycerides by MR (1,15)
were not compromised in Fgf212/2 mice, establishing that
FGF21 is not the mediator of these effects of MR in the
liver. We previously showed that addition of small amounts
of cysteine to the MR diet fully reversed the transcriptional
activation of hepatic Fgf21 by MR (13) but that the down-
regulation of Scd1 was unaffected. However, the activation
of NRF2- and ATF4-sensitive genes by MR in the liver was
reversed by adding cysteine back to the diet (13), supporting
our view that these transcriptional effects of MR are directly
linked to methionine/cysteine sensing in the liver and are
not secondary to FGF21. However, MR was unable to reduce
serum triglyceride in Fgf212/2 mice, suggesting a require-
ment for FGF21 for this effect. We believe this effect is
associated with FGF21-dependent remodeling of BAT and
WAT and the enhanced clearance of serum triglycerides by
enhanced thermogenesis (56). Recent work showed that
FGF21 lowered plasma triglycerides by accelerating lipopro-
tein catabolism in WAT and BAT (57). Thus, the failure of
MR to decrease serum triglycerides in Fgf212/2 mice was
due to the inability of MR to enhance thermogenic activ-
ity in BAT and WAT in the absence of FGF21. It will be
important to test this hypothesis experimentally using
tracer-based methods to measure fatty acid uptake and
utilization among tissues. On the basis of the present
findings, we propose that FGF21 is a key mediator linking
sensing of the reduction of dietary methionine in the liver
to its effects on energy balance, insulin sensitivity, and
adipose tissue remodeling, but not its transcriptional ef-
fects in the liver.
Acknowledgments. The authors thank Kelly Dille, Kodi Bethay, and
Jaroslaw Staszkiewicz from the corresponding author’s laboratory at Pennington
Biomedical Research Center for excellent technical support and Dr. Chris Morri-
son of the Pennington Biomedical Research Center for helpful discussions during
the preparation of the manuscript. The authors thank Cindi Tramonte (Pennington
Biomedical Research Center) for administrative support.
Funding. D.W. is supported by a National Institute of Diabetes and Digestive
and Kidney Diseases National Institutes of Health (NIH) National Research Service
Award (NIH NRSA 1-F32-DK-098918). L.A.F. is supported by an American Di-
abetes Association mentor-based postdoctoral fellowship (7-13-MI-05). This
work was partly supported by American Diabetes Association grant 1-12-BS-58
(T.W.G.), National Institute of Diabetes and Digestive and Kidney Diseases grant
NIH R01-DK-096311 (T.W.G.), and the Mouse Metabolic Phenotyping Center
Consortium (NIH U24-DK-059637). This work also made use of the Genomics
and Cell Biology & Bioimaging core facilities supported by National Institute of
General Medical Sciences grant NIH 3P30 GM118430 (T.W.G.). This research
project used the Transgenic and Animal Phenotyping core facilities that are
supported in part by the National Institute of Diabetes and Digestive and Kidney
Diseases Nutrition Obesity Research Centers grant NIH 3P30-DK-072476.
Duality of Interest. No potential conflicts of interest relevant to this article
were reported.
Author Contributions. D.W., L.A.F., and T.W.G. contributed to the writing
and editing of the manuscript. D.W., L.A.F., K.P.S., and A.P. conducted the animal
experiments, the in vitro analysis, and the associated Western blots, mRNA, and
metabolite measurements. L.A.F. and T.W.G. and analyzed the data used to produce
illustrations. D.H.B. conducted the imaging analysis. T.W.G. is the guarantor of this
work and, as such, had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis.
References
1. Hasek BE, Boudreau A, Shin J, et al. Remodeling the integration of lipid
metabolism between liver and adipose tissue by dietary methionine restriction in
rats. Diabetes 2013;62:3362–3372
2. Hasek BE, Stewart LK, Henagan TM, et al. Dietary methionine restriction
enhances metabolic flexibility and increases uncoupled respiration in both fed
and fasted states. Am J Physiol Regul Integr Comp Physiol 2010;299:R728–R739
3. Malloy VL, Krajcik RA, Bailey SJ, Hristopoulos G, Plummer JD, Orentreich N.
Methionine restriction decreases visceral fat mass and preserves insulin action in aging
male Fischer 344 rats independent of energy restriction. Aging Cell 2006;5:305–314
4. Wanders D, Burk DH, Cortez CC, et al. UCP1 is an essential mediator of the
effects of methionine restriction on energy balance but not insulin sensitivity.
FASEB J 2015;29:2603–2615
5. Stone KP, Wanders D, Orgeron M, Cortez CC, Gettys TW. Mechanisms of
increased in vivo insulin sensitivity by dietary methionine restriction in mice.
Diabetes 2014;63:3721–3733
6. Kimball SR. Regulation of global and specific mRNA translation by amino
acids. J Nutr 2002;132:883–886
7. Kobayashi H, Børsheim E, Anthony TG, et al. Reduced amino acid availability
inhibits muscle protein synthesis and decreases activity of initiation factor eIF2B.
Am J Physiol Endocrinol Metab 2003;284:E488–E498
8. Zhang P, McGrath BC, Reinert J, et al. The GCN2 eIF2alpha kinase is re-
quired for adaptation to amino acid deprivation in mice. Mol Cell Biol 2002;22:
6681–6688
9. Gietzen DW, Ross CM, Hao S, Sharp JW. Phosphorylation of eIF2alpha is
involved in the signaling of indispensable amino acid deficiency in the anterior
piriform cortex of the brain in rats. J Nutr 2004;134:717–723
10. Deval C, Chaveroux C, Maurin AC, et al. Amino acid limitation regulates the
expression of genes involved in several specific biological processes through
GCN2-dependent and GCN2-independent pathways. FEBS J 2009;276:707–718
11. Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H, Kilberg MS. ATF4 is a mediator
of the nutrient-sensing response pathway that activates the human asparagine
synthetase gene. J Biol Chem 2002;277:24120–24127
12. Pan Y, Chen H, Siu F, Kilberg MS. Amino acid deprivation and endoplasmic
reticulum stress induce expression of multiple activating transcription factor-3
866 Effects of MR Mediated by FGF21 Diabetes Volume 66, April 2017
mRNA species that, when overexpressed in HepG2 cells, modulate transcription by
the human asparagine synthetase promoter. J Biol Chem 2003;278:38402–38412
13. Wanders D, Stone KP, Forney LA, et al. Role of GCN2-independent signaling
through a non-canonical PERK/NRF2 pathway in the physiological responses to
dietary methionine restriction. Diabetes 2016;65:1499–1510
14. Plaisance EP, Henagan TM, Echlin H, et al. Role of b-adrenergic receptors in
the hyperphagic and hypermetabolic responses to dietary methionine restriction.
Am J Physiol Regul Integr Comp Physiol 2010;299:R740–R750
15. Stone KP, Wanders D, Calderon LF, Spurgin SB, Scherer PE, Gettys TW.
Compromised responses to dietary methionine restriction in adipose tissue but
not liver of ob/ob mice. Obesity (Silver Spring) 2015;23:1836–1844
16. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 cor-
rects obesity in mice. Endocrinology 2008;149:6018–6027
17. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis
controls energy expenditure and insulin action in mice. Cell Metab 2013;17:790–797
18. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel met-
abolic regulator. J Clin Invest 2005;115:1627–1635
19. Adams AC, Coskun T, Rovira AR, et al. Fundamentals of FGF19 & FGF21
action in vitro and in vivo. PLoS One 2012;7:e38438
20. Xu J, Stanislaus S, Chinookoswong N, et al. Acute glucose-lowering and
insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association
with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009;297:
E1105–E1114
21. Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and
circadian behavior by acting on the nervous system. Nat Med 2013;19:1147–1152
22. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic
steatosis, increases energy expenditure, and improves insulin sensitivity in diet-
induced obese mice. Diabetes 2009;58:250–259
23. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as
metabolic regulators–a critical appraisal. Cell Metab 2012;16:693–705
24. Ghosh S, Wanders D, Stone KP, Van NT, Cortez CC, Gettys TW. A systems
biology analysis of the unique and overlapping transcriptional responses to caloric
restriction and dietary methionine restriction in rats. FASEB J 2014;28:2577–2590
25. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the
design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes
2006;55:390–397
26. Wanders D, Stone KP, Dille K, Simon J, Pierse A, Gettys TW. Metabolic
responses to dietary leucine restriction involve remodeling of adipose tissue and
enhanced hepatic insulin signaling. Biofactors 2015;41:391–402
27. Patil YN, Dille KN, Burk DH, Cortez CC, Gettys TW. Cellular and molecular
remodeling of inguinal adipose tissue mitochondria by dietary methionine re-
striction. J Nutr Biochem 2015;26:1235–1247
28. Orentreich N, Matias JR, DeFelice A, Zimmerman JA. Low methionine in-
gestion by rats extends life span. J Nutr 1993;123:269–274
29. Zimmerman JA, Malloy V, Krajcik R, Orentreich N. Nutritional control of
aging. Exp Gerontol 2003;38:47–52
30. Miller RA, Buehner G, Chang Y, Harper JM, Sigler R, Smith-Wheelock M.
Methionine-deficient diet extends mouse lifespan, slows immune and lens aging,
alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels
and stress resistance. Aging Cell 2005;4:119–125
31. Sun L, Sadighi Akha AA, Miller RA, Harper JM. Life-span extension in mice
by preweaning food restriction and by methionine restriction in middle age.
J Gerontol A Biol Sci Med Sci 2009;64:711–722
32. Richie JP Jr, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N,
Zimmerman JA. Methionine restriction increases blood glutathione and lon-
gevity in F344 rats. FASEB J 1994;8:1302–1307
33. Lees EK, Król E, Grant L, et al. Methionine restriction restores a younger
metabolic phenotype in adult mice with alterations in fibroblast growth factor 21.
Aging Cell 2014;13:817–827
34. Ables GP, Perrone CE, Orentreich D, Orentreich N. Methionine-restricted
C57BL/6J mice are resistant to diet-induced obesity and insulin resistance but
have low bone density. PLoS One 2012;7:e51357
35. Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of
FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013;
17:779–789
36. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1a and
browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012;
26:271–281
37. Emanuelli B, Vienberg SG, Smyth G, et al. Interplay between FGF21 and
insulin action in the liver regulates metabolism. J Clin Invest 2014;124:515–527
38. Véniant MM, Sivits G, Helmering J, et al. Pharmacologic effects of FGF21
are independent of the “browning” of white adipose tissue. Cell Metab 2015;21:
731–738
39. Samms RJ, Smith DP, Cheng CC, et al. Discrete aspects of FGF21 in vivo
pharmacology do not require UCP1. Cell Reports 2015;11:991–999
40. Ding X, Boney-Montoya J, Owen BM, et al. bKlotho is required for fibroblast
growth factor 21 effects on growth and metabolism. Cell Metab 2012;16:387–393
41. Adams AC, Yang C, Coskun T, et al. The breadth of FGF21’s metabolic
actions are governed by FGFR1 in adipose tissue. Mol Metab 2012;2:31–37
42. Camacho RC, Zafian PT, Achanfuo-Yeboah J, Manibusan A, Berger JP.
Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-
induced insulin resistant mice. Eur J Pharmacol 2013;715:41–45
43. Bröer A, Juelich T, Vanslambrouck JM, et al. Impaired nutrient signaling and
body weight control in a Na+ neutral amino acid cotransporter (Slc6a19)-
deficient mouse. J Biol Chem 2011;286:26638–26651
44. Jiang Y, Rose AJ, Sijmonsma TP, et al. Mice lacking neutral amino acid
transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and
improved glycaemic control. Mol Metab 2015;4:406–417
45. Markan KR, Naber MC, Ameka MK, et al. Circulating FGF21 is liver derived
and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014;
63:4057–4063
46. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce
sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab
2014;20:670–677
47. Douris N, Stevanovic DM, Fisher FM, et al. Central fibroblast growth factor
21 browns white fat via sympathetic action in male mice. Endocrinology 2015;
156:2470–2481
48. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibro-
blast growth factor 21-deficient mice demonstrate impaired adaptation to ke-
tosis. Endocrinology 2009;150:4931–4940
49. Camporez JP, Asrih M, Zhang D, et al. Hepatic insulin resistance and in-
creased hepatic glucose production in mice lacking Fgf21. J Endocrinol 2015;
226:207–217
50. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor
21 (FGF21)-resistant state. Diabetes 2010;59:2781–2789
51. Singhal G, Fisher FM, Chee MJ, et al. Fibroblast growth factor 21 (FGF21)
protects against high fat diet induced inflammation and islet hyperplasia in
pancreas. PLoS One 2016;11:e0148252
52. Laeger T, Henagan TM, Albarado DC, et al. FGF21 is an endocrine signal of
protein restriction. J Clin Invest 2014;124:3913–3922
53. Guo F, Cavener DR. The GCN2 eIF2alpha kinase regulates fatty-acid ho-
meostasis in the liver during deprivation of an essential amino acid. Cell Metab
2007;5:103–114
54. Cheng Y, Zhang Q, Meng Q, et al. Leucine deprivation stimulates fat loss via
increasing CRH expression in the hypothalamus and activating the sympathetic
nervous system. Mol Endocrinol 2011;25:1624–1635
55. Cheng Y, Meng Q, Wang C, et al. Leucine deprivation decreases fat mass by
stimulation of lipolysis in white adipose tissue and upregulation of uncoupling
protein 1 (UCP1) in brown adipose tissue. Diabetes 2010;59:17–25
56. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls
triglyceride clearance. Nat Med 2011;17:200–205
57. Schlein C, Talukdar S, Heine M, et al. FGF21 lowers plasma triglycerides by
accelerating lipoprotein catabolism in white and brown adipose tissues. Cell
Metab 2016;23:441–453
diabetes.diabetesjournals.org Wanders and Associates 867
